Rocket Pharmaceuticals is developing adeno-associated virus (“AAV”) gene therapies to target genetic CV indications caused by mutations or defects in different genes.
Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback